The $500M convertible offering significantly extends Celcuity's cash runway through potential FDA approval and commercialization of gedatolisib, but introduces dilution risk at a ~40% premium. Monitor the June 8 closing and any subsequent updates on the NDA review (PDUFA date not stated). Given the negative historical T+20 performance on CELC reports and the mixed nature of this event (capital infusion vs. dilution), traders should watch for near-term volatility around the offering close and potential overhang from the conversion option.
Price Chart
Executive Summary
Celcuity priced a $500M upsized convertible senior notes offering (0.250% coupon, due 2032), increased from $400M, with an underwriter option for an additional $75M. Net proceeds of ~$484.3M (or ~$557M with over-allotment) will repay Oxford Finance debt and fund working capital, including clinical trials and potential commercialization. The conversion premium of ~40% above the last sale price signals moderate dilution risk, but the large capital raise provides a multi-year cash runway for a pre-revenue biotech awaiting FDA action on gedatolisib.
Key Financial Metrics
Key Facts
- Upsized convertible notes offering: $500M aggregate principal, increased from $400M.
- 0.250% coupon, maturing August 1, 2032; semi-annual interest payments.
- Initial conversion price ~$124.53 per share, ~40% premium above last reported sale price on June 3, 2026.
- Underwriters have 30-day option to purchase up to an additional $75M in notes for over-allotments.
- Net proceeds estimated at ~$484.3M (or ~$557M if over-allotment exercised in full).
- Proceeds to repay all outstanding obligations under Oxford Finance loan agreement; remainder for working capital, clinical trials, and potential commercialization.
- Offering expected to close June 8, 2026, subject to customary conditions.
- Company is clinical-stage, pre-revenue, with lead candidate gedatolisib in Phase 3 for HR+/HER2- breast cancer.
- Conversion premium of 40% provides some cushion against near-term dilution, but full conversion at $124.53 would add significant share count.
- Historical performance on CELC reports shows negative average returns at T+20 (-2.23%) and low win rate (33%), suggesting caution.
Financial Impact
Net proceeds of ~$484.3M (or ~$557M with over-allotment) provide substantial capital for a pre-revenue biotech with ~$4.3B market cap. Full conversion at $124.53 would add ~4.0M shares (based on $500M / $124.53), representing roughly 5-6% dilution relative to current shares outstanding (estimated from market cap and stock price). The 0.250% coupon is minimal interest expense.
Risk Factors
- Dilution risk: Full conversion of notes at $124.53 would add ~4M shares, potentially pressuring stock price.
- Execution risk: Proceeds used for clinical trials and commercialization; failure of gedatolisib to gain FDA approval would leave company with high cash burn and no revenue.
- Market risk: Convertible notes may create overhang if stock trades near conversion price, encouraging arbitrage activity.
- Historical calibration: Past CELC reports show negative average T+20 returns (-2.23%) and low win rate (33%), suggesting the market may react negatively to this capital raise despite the cash infusion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306482 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 26, 2026 5w ago | 8-K | $95.08 $84.00 | ▼ −11.65% | ▼ −12.86% | $72.51 (−23.74%) |
Jul 15, 2026 11w ago | 144 | $91.51 $92.08 | ▼ −0.62% | ▲ +1.72% | $72.51 (+20.76%) |
Jul 14, 2026 11w ago | Press Release | $91.51 $92.08 | ▲ +0.62% | ▼ −1.72% | $72.51 (−20.76%) |
Jun 11, 2026 16w ago | Institutional Cluster | $89.49 $113.51 | ▲ +26.84% | ▲ +24.95% | $72.51 (−18.97%) |
Jun 8, 2026 16w ago | 8-K | $92.59 $115.72 | ▲ +24.98% | ▲ +23.53% | $72.51 (−21.69%) |
Jun 5, 2026 17w ago | 424B5 | $88.28 $108.58 | ▲ +23.00% | ▲ +21.13% | $72.51 (−17.86%) |
Jun 4, 2026 17w ago | Press Release | $92.47 $107.95 | ▲ +16.74% | ▲ +18.11% | $72.51 (−21.59%) |
Jun 3, 2026 17w ago | Press Release | $88.95 $107.95 | ▼ −21.36% | ▼ −22.36% | $72.51 (+18.48%) |
Jun 3, 2026 17w ago | 424B5 | $88.95 $107.95 | ▼ −21.36% | ▼ −22.36% | $72.51 (+18.48%) |
Jun 2, 2026 17w ago | 8-K | $91.42 $104.49 | ▲ +14.30% | ▲ +15.86% | $72.51 (−20.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access